The transcriptomic and proteomic characterisation of CD4 + T cells at the single-cell level has been performed traditionally by two largely exclusive types of technologies: single cell RNAsequencing (scRNA-seq) technologies and antibody-based cytometry. Here we demonstrate that the simultaneous targeted quantification of mRNA and protein expression in single-cells provides a high-resolution map of human primary CD4 + T cells, and identified precise trajectories of Th1, Th17 and regulatory T-cell (Treg) differentiation in blood and tissue. Furthermore, the sensitivity provided by this massively-parallel multi-omics approach revealed novel insight into the mechanism of expression of CD80 and CD86 on the surface of activated CD4 + Tregs and demonstrate their potential to identify recently activated T cells in circulation. This transcriptomic and proteomic hybrid technology provides a cost-effective solution to dissect the heterogeneity of immune cell populations, including more precise and detailed descriptions of the differentiation and activation of circulating and tissue-resident cells in response to therapies and in stratification of patients.
Background
Our understanding of the human immune system has been greatly influenced by the technological advances leading to the ability to precisely quantify mRNA and/or protein expression at the single-cell level. In particular, the implementation of flow cytometry as a routine and widely-accessible research tool has shaped much of our current knowledge about the complexity of the immune system. With increased availability of fluorochrome-conjugated antibodies and more powerful lasers, flow-cytometric assays allow typically 15-20 parameters that can be assessed in parallel. Developments in single-cell mass cytometry (CyTOF) have similarly allowed the simultaneous assessment of the expression of up to 50 protein targets using heavy metal-labeled antibodies [1] .
The advent of single-cell RNA-sequencing (scRNA-seq) has provided an unprecedented opportunity to investigate the global transcriptional profile at the single-cell level. In contrast to cytometry-based technologies, which are limited to the concurrent detection of up to a few tens of protein markers, scRNA-seq technologies allow to profile the entire transcriptome. With the concomitant reduction in sequencing costs, there has been a recent explosion in scRNA-seq platforms available to immunologists [2, 3] . These fundamentally differ in the cell capture methods and resulting sensitivity, ranging from a few hundreds of cells profiled with high sensitivity, using plate-based capture methods such as SMART-seq2 [4] , tens of thousands of cells with lower sensitivity using whole-transcriptome scRNA-seq platforms, such as 10X Genomics [5] , Seq-Well [6] or Drop-seq [7] .
Despite the growing popularity of whole-transcriptome scRNA-seq, two main issues still affect the performance of these platforms: cost and sensitivity. Even at high sequencing coverage, resulting in increased sequencing costs, stochastic dropout is a well-known issue of scRNA-seq, leading to an inflation of zero-expression measurements. Furthermore, although several methods have been developed to impute missing expression values, questions remain about the performance of these methods [8] . This technical limitation is particularly relevant for resting primary cells, such as CD4 + T cells, and mainly limits the robust detection and quantification of lowly expressed genes, including lineage-defining transcription factors, which are critical for cell-type identification and annotation. An important recent technical advance has been the development of new methods, such as CITE-seq [9] and REAP-seq [10] , allowing the combination of whole- 4 transcriptome scRNA-seq with measurement of protein expression at the single-cell level using oligo-conjugated antibodies. These methods provide critical insight into cell function and increased clustering resolution, although the resulting sequencing cost, especially when combining large numbers of antibodies targeting highly expressed proteins, still limits the use of this technology as a widely-applicable immunophenotyping tool.
In this study we describe an integrated targeted scRNA-seq workflow, to simultaneously quantify the expression of 397 genes at the mRNA level and up to 68 genes at the protein level with oligo-conjugated antibodies (AbSeq) [11] . We sought to assess the sensitivity and costeffectiveness of this multi-omics system to immunophenotype human primary CD4 + T cells at the single-cell level, and to identify discrete cell-states providing potential new insight into the functional heterogeneity of T cells. By combining the expression of a targeted set of genes with the highly quantitative measurement of key protein markers, we have generated a high-resolution map of human CD4 + T cells in blood and tissue, and delineated distinct trajectories of T-cell differentiation associated with a gradient of activation, which were apparent even in resting primary cells. Our data also shows very clearly the frequent low correlation between mRNA and protein expression in primary CD4 + T cells, thereby challenging the current dogma that our current understanding of the immune system can be re-defined based on single-cell transcriptional data alone. These attributes provided novel evidence for the potential mechanisms leading to the expression of exogenous CD80 and CD86 on the surface of human primary Tregs, thus revealing a biomarker for activated Tregs that have recently contacted antigen presenting cells expressing these T-cell co-stimulatory signaling molecules.
Results

Simultaneous protein quantification increases the power of scRNA-seq to dissect the functional heterogeneity of human CD4 + T cells
In this study we wanted to investigate the power of a unified high-throughput experimental workflow combining targeted scRNA-seq and the quantification of protein expression at the single-cell level to dissect the heterogeneity of resting human primary CD4 + T cells in blood. To address this question, we initially profiled the expression of 397 genes at the mRNA level, coupled with 37 protein targets (Table S1) using the AbSeq technology [11] in CD4 + T cells isolated from blood of a systemic lupus erythematosus (SLE) patient. To enrich for the relative distribution of two less abundant CD4 + T-cell subsets: (i) CD127 low CD25 + T cells, containing the Treg population; and (ii) CD127 low CD25 low T cells, containing a subset of non-conventional CD25 low FOXP3 + Tregs previously characterised in autoimmune patients [12] , we devised a FACSsorting strategy to isolate and profile equal numbers of cells from the three defined T-cell subsets ( Fig. 1a) . Following FACS sorting, cells from each subset were labeled with a barcoded oligoconjugated antibody (sample tag) prior to cell loading -a method related to the recently described cell-hashing technique [13] -to identify their original sorting gate and to assess the frequency of cell multiplets obtained in this experiment.
A total of 9,898 captured cells passed initial QC, of which a small proportion (1.9%; Table   S2 ) were assigned as multiplets and excluded from the analysis. Of note, we observed complete sequencing saturation of the mRNA library, assessed as the number of cDNA molecules with a novel Unique Molecular Identifier (UMI) identified with increasing sequencing coverage, for a coverage of <3,000 reads/cell ( Fig. S1a) . In contrast, we obtained an 80% sequencing saturation at a coverage of >6,000 reads/cell for the AbSeq library ( Fig. S1b) . This is illustrated in the large dynamic range of expression of the protein targets, reaching up to thousands of unique copies in cells displaying higher levels of expression ( Fig. S1c) . Of note, the distribution of most proteins, including all those that are known not to be expressed on CD4 + T cells was centered around zero copies ( Fig. S1c) , which demonstrates the high specificity of the AbSeq immunostainings. To further test the sensitivity of the AbSeq protein measurements, we next generated a two- 6 dimensional plot depicting the AbSeq expression of IL-2RA (CD25) and IL-7R (CD127), which we found to recapitulate the flow cytometric profile obtained with the same two markers used for the FACS-sorting of the assessed T-cell subsets ( Fig. 1b) . Furthermore, by overlaying the sampletag information, we were able to confirm that the expression profiles of CD127 and CD25 mimicked the sorting strategy precisely for all three subsets ( Fig. 1b) , therefore illustrating the highly quantitative nature of the protein measurements.
Next we performed unsupervised hierarchical clustering combining the mRNA and protein expression data and visualised the clusters in a two-dimensional space using Uniform Manifold Approximation and Projection (UMAP) [14] . One of the main drivers of functional differentiation in CD4 + T cells is the acquisition of a memory phenotype in response to antigen stimulation, typically marked by the expression of CD45RA on naïve cells and CD45RO on memory cells.
However, because these are splice forms of the same gene (PTPRC; CD45), its discrimination cannot be achieved using UMI-based scRNA-seq systems targeting the 3' or 5' ends of the transcript. By measuring the expression of the two isoforms at the protein level, we were able to identify a marked expression gradient associated with a gradual loss of CD45RA and concomitant gain of CD45RO along the first component of the UMAP plot, indicating that the acquisition of a memory phenotype is indeed the main source of biological variation driving the clustering of CD4 + T cells ( Fig. 1c) . One notable exception was the re-expression of CD45RA in the most differentiated memory cells ( Fig. 1c) . This observation is consistent with the phenotype of differentiated effector memory CD4 + T cells that re-express CD45RA (TEMRAs) [15] , and illustrates the power of this highly multiparametric approach to identify subtle alterations in CD4 + T-cell states, while mitigating the potential issue of cell-type misclassification based on a few prototypical markers such as CD45RA/RO.
Single-cell mRNA and protein immunophenotyping identifies distinct trajectories of CD4 + T cell differentiation in blood
Integration of the multiparametric transcriptional and proteomics data generated provided distinct clustering of CD4 + T cells into discrete clusters along the naïve/memory differentiation 7 axis ( Fig. 1d) . We observed an increased number of clusters within the memory compartment, marked by the differential expression of defined sets of signature genes ( Fig. 1e and Fig. S2a) , which was consistent with the increased phenotypic diversity in differentiated CD4 + T-cell subsets.
Moreover, we observed that the expression of the canonical Th1 (TBX21, encoding TBET) and
Th17 (RORC, encoding RORgt) lineage-defining transcription factors was restricted to specific clusters within the effector memory T-cell (mTeff) population ( Fig. 1f) , indicating that these clusters are highly enriched for Th1 and Th17 Teffs. More importantly, we observed a distinct gradient of expression of these transcription factors. Consistent with this gradient of functional differentiation, we observed a marked co-expression of canonical Th1 effector-type molecules with the expression of TBET ( Fig. 1f) , revealing a subset of highly activated Th1 T cells with a putative cytotoxic profile in the blood of this SLE patient. Similarly, a gradient of expression of Th17-signature genes, including RORC, could be observed from cluster 8 to 7 (Fig. 1e,f) , indicating a trajectory of Th17 differentiation.
In addition to resting CD4 + T cells, we also profiled the same subsets of cells following short in vitro stimulation (90 min) with PMA + ionomycin, to assess cell-type specific cytokine production. Similarly to the resting condition, in vitro stimulated CD4 + T cells formed discrete clusters along the naïve-memory differentiation axis ( Fig. S3a,b) . Furthermore, we observed a consistent induction of expression of Th1 (IFNg) and Th17 (IL-22) type cytokines that were restricted to the respective Th1 and Th17 clusters (Fig S3c,d) . Furthermore, although primers for the Th2 transcription factor GATA-3 were not included in this assay, therefore precluding the annotation of Th2 cells in resting CD4 + T cells, we noted that in vitro stimulation revealed a distinct cluster of Th2 mTeffs cells marked by the expression of Th2-type cytokines, such as IL-13 ( Fig   S3e) , but also IL-4, IL-5 and IL-9 ( Fig. S2b) .
Recently, several scRNA-seq studies have refined our understanding of the heterogeneity of CD4 + Tregs and their functional adaptation in tissues, in both mice and humans [16, 17] . Given the sorting strategy used in this study, we were able to significantly enrich our CD4 + T-cell dataset for the Treg population, which is highly enriched within the CD127 low CD25 hi population.
Consistent with this enrichment strategy, we identified a large Treg population marked by the expression of the transcription factor FOXP3, but also other classical Treg signature genes, including HELIOS (encoded by IKZF2), IL-2RA, CTLA-4 or TIGIT ( Fig. 2a,b) . In agreement 8 with their Treg-specific transcriptional programme, we found a marked suppression of IL-2 transcription in Tregs following in vitro stimulation ( Fig. S3f) . Notably, we found that the differentiation of Tregs from a naïve to memory phenotype was strongly associated with the expression of two transcription factors: BACH2 and BLIMP1 (encoded by PRDM1). These two key transcription factors displayed a very distinct mutually exclusive expression pattern, with high expression of BACH2 in naïve cells, declining gradually -with concomitant gradual increase in PRDM1 expression -along the naïve-memory differentiation axis (Fig. 2c) . The gradual increase of PRDM1 expression was found to be strongly associated with the expression of Treg activation markers such as HLA-DRA, DUSP4 and CD39 (Fig. 2d) , and revealed a trajectory of Treg activation in resting primary CD4 + T cells. These data suggest that the transcriptional interplay between BACH2 and BLIMP-1 is critical to regulate the differentiation of memory Treg subsets, which is in agreement with previous data in both mouse and humans [16] . The dynamic interplay of BACH2 and PRDM1 in the differentiation of Tregs was even more pronounced following in vitro stimulation ( Fig. S4) , which further supports the hypothesis that they are primary regulators of the transcriptional programme associated with the differentiation of suppressive activated Tregs in humans in response to antigen stimulation.
Statistical methods are currently being developed to identify and reconstruct developmental trajectories from heterogeneous scRNA-seq datasets using pseudotime analysis. To validate our findings, we next applied the recently developed partition-based graph abstraction (PAGA) method [18] to reconstruct the developmental trajectories in our dataset. Consistent with our previous findings, pseudotime analysis revealed a gradient of T-cell differentiation along the naïve-memory differentiation axis, which lead to the identification of three distinct differentiation pathways associated with the acquisition of a Th1, Th17 or Treg phenotype (Fig. 3a,b) . These identified differentiation trajectories were associated with gradual increased expression of the lineage-specific transcription factors TBET, RORgt and FOXP3, which regulate the transcriptional programme associated with the respective T-cell lineages ( Fig. 3c-e ). In particular, we confirmed a very distinct and gradual differentiation of the Th1 lineage in this SLE patient, leading to the temporal acquisition of activated Th1 cells expressing IFN-g in cluster 5 and the terminal differentiation of a subset with cytotoxic profile (cluster 9). Of note, this analysis identified cluster 2 as an intermediate memory Teff cell state, leading to the differentiation of either Th1 (cluster 5 9 and 9) or Th17 (cluster 7) T cells. Moreover, pseudotime analysis also recapitulated the acquisition of an activated Treg trajectory from naïve Tregs (cluster 0) to activated memory Tregs (cluster 3), which was regulated by the mutually exclusive expression of the BACH2 and BLIMP-1 transcription factors (Fig. 3e ). An intriguing observation was the identification of cluster 8 representing a potential intermediate T-cell state on a Treg-Th17 developmental pathway, which is consistent with the plasticity and putative common co-evolutionary origin between these two lineages [19] .
The identification of the temporal differentiation of these T-cell lineages was also recapitulated using Single-cell Trajectories Reconstruction (STREAM) [20] , another method that has been developed to visualise developmental trajectories using multi-omics data ( Fig. 3f ). (Fig. 3g) . These data illustrate not only the sensitivity of the targeted scRNA-seq approach to sensitively quantify lowly expressed transcription factor genes, but also highlight the power of this integrated multi-omics approach to identify subtle cell-state transitions. The large number of captured single-cells and the combination of protein and mRNA measurement that we obtained in this study makes this dataset particularly well suited to identify continuous cell-state transitions and reconstruct the differentiation trajectories from resting human primary T cells.
Protein expression of CD80 and CD86 marks a subset of recently activated D4 + Tregs in circulation.
A feature of the most activated Treg cluster (cluster 3), was the marked increased expression of CD80 and CD86 at the protein level ( Fig. 2b,d) , two T-cell costimulatory molecules usually expressed in antigen presenting cells (APCs). These findings were recapitulated on the pseudotime analysis, which identified CD80/CD86 protein expression as markers of the temporal Treg differentiation trajectory ( Fig. 3e) . Consistent with their APC-restricted expression pattern, 10 we observed virtually no detectable expression of either CD80 or CD86 at the mRNA level in either resting or in vitro stimulated CD4 + T cells ( Fig. 4a,b ), suggesting a likely exogenous source of the detected protein expression.
Recently, two mechanisms have been postulated to lead to the expression of APC-restricted proteins on the surface of activated T-cells, and Tregs in particular: (i) a CTLA-4 dependent mechanism (trans-endocytosis), whereby CTLA-4 expression on the surface of activated T cells can lead to the removal and subsequent endolytic degradation of CD80/CD86 molecules from the surface of APCs [21] ; and (ii) a TCR-dependent mechanism (trogocytocis), whereby TCR engagement with the peptide-MHC complex on APCs can lead to the re-expression of APCrestricted molecules on the surface of activated T cells [22] . To validate the detected expression of CD80 and CD86 in human resting primary CD4 + T cells, and to shed light into the mechanisms of expression, we next designed a flow cytometry panel to investigate the expression of these proteins in CD4 + T cells isolated from blood of two healthy donors. We differentiated between surface and intracellular expression of the assessed markers by performing immunostaining either prior or following cell fixation and permeabilisation. Consistent with this strategy, we confirmed that although the expression of CTLA-4 on the surface of CD4 + T cells is very low, intracellular staining revealed much higher expression, most notably in the different Treg subsets ( Fig. 4c,d) .
Notably, we detected a remarkable co-expression between CD86 and CTLA-4. In fact, CD86 expression was only detected on CTLA-4 hi T cells, and was therefore mainly restricted to memory Treg (mTreg) subsets, on the cells expressing the higher levels of CTLA-4 ( Fig. 4e ). In addition, we also observed a strong co-expression of CD86 and HLA-DR, another marker associated with Treg activation (Fig. 4f) . In contrast to CD86, the co-expression between CD80 and CTLA-4 on mTregs was less pronounced, although still displaying preferential expression on CTLA-4 hi cells ( Fig. 4g ). Furthermore, we also observed notable differences in the cellular location of CD80 and CD86 expression. While CTLA-4 and CD86 displayed a predominantly intracellular location, expression of CD80 was mostly restricted to the surface of the cells and was detected at similar levels using either surface or intracellular immunostaining ( Fig. 4h) . Taken together, these data reveal novel insight into the specific mechanisms of CD80 and CD86 protein expression on the surface of human Tregs, and suggest that they could be useful as novel biomarkers of recently 11 activated T cells in the circulation and indicative of their engagement with CD80/CD86-expressing APCs.
Multi-omics immunophenotyping approach identifies a rare subset of circulating CCR9 +
Tregs displaying hallmarks of tissue-resident T cells
Another example of a rare T-cell population that we were able to identify in circulation using this multimodal immunophenotyping strategy was a subset of FOXP3 + T cells marked by the specific expression of the small intestine-homing chemokine receptor CCR9 (cluster 10; Fig.   2e ). This cluster was also marked by increased expression of other classical markers of tissue residency and migration to the gut, such as ITGA4 (CD49d) and ITGAE (CD103; Fig. 2e ). One distinguishing feature of this subset was the expression of the transcription factor POU2AF1 ( Fig.   2e ). Although POU2AF1 (encoding OCA-B), has been mainly characterised as a B-cell specific transcription factor in blood, where it plays a role in B-cell maturation [23] , it has also been recently shown in mice to regulate the maintenance of memory phenotype and function in previously activated CD4 + T cells [24] , and the differentiation of T follicular helper (Tfh) cells in the tissue [25] . In agreement with this putative tissue-resident phenotype, pseudotime analysis demonstrated that these cells correspond to a highly differentiated cell state ( Fig. 3a) . These data suggest that this subset of CCR9 + T cells may represent a previously uncharacterised population of recirculating tissue-resident Tregs in humans, and provides an illustrative example of the power of this multiparametric immunophenotyping approach to identify rare immune populations and reveal novel insight into the biology of CD4 + T cells.
Single-cell comparison of mRNA and protein expression levels reveals modest and variable levels of correlation in primary CD4 + T cells
Given that the main advantage of this combined targeted scRNA-seq and proteomic approach is the ability to immunophenotype large numbers of cells from multiple donors, we next investigated whether we were able to integrate data generated from independent experiments. We 12 replicated the initial experiment using the same pre-sorting strategy to isolate the three assessed CD4 + T-cell subsets from an individual with type 1 diabetes and one healthy donor. To further test the potential of the protein quantification, we extended the AbSeq panel to 43 protein targets expressed on CD4 + T cells (Table S1 ). In agreement with the initial experiment, unsupervised clustering of the 23,947 cells passing QC revealed a similar discrimination of CD4 + T-cell subsets ( Fig. 5a) . More importantly, we found very good alignment of the data from the three donors, with minimal evidence of significant experimental batch effects ( Fig. 5b) . Analysis of the donorspecific distribution of the identified CD4 + T-cell clusters also showed that the frequency of the putative CD4 + cytotoxic Th1 subset (cluster 11), marked by the co-expression of TBET and effector-type cytokines, was highly increased in the SLE patient ( Fig. 5c-e ). To avoid age-specific differences in the relative distribution of the CD45RA + naïve and CD45RO + memory compartments in these donors, we normalised the analysis to the memory T-cell clusters only, which we were able to robustly annotate using the AbSeq data for the expression of CD45RA and CD45RO. Although we detected a few cells with this activated Th1 phenotype in circulation from every donor, there was a very substantial expansion in the SLE patient (2.5% of memory CD4 + T cells compared to 0.3% and 0.1% in the T1D patient and healthy donor, respectively; Fig. 5d ), suggesting that it could represent a pathogenic CD4 + T-cell subset associated with systemic autoimmunity in this patient.
The parallel quantification of mRNA and protein expression for a large number of genes expressed in CD4 + T cells in this experiment provided a unique opportunity to investigate their systematic correlation at the single-cell level. From the 43 proteins quantified with AbSeq, 26 were also assessed at the transcriptional level and detected in our CD4 + T-cell dataset. Generally, we observed relatively weak (mean Pearson correlation coefficient = 0.214) but variable levels of correlation in total resting CD4 + T cells, ranging from 0.049 for TNFRSF9 to 0.808 in KLRB1 (encoding CD161; Fig. 5f ). Furthermore, we note that with the exception of CXCR5, the estimated correlations were very consistent between the two independent donors (Fig. 5f) . These findings were consistent with previous observations [9, 10] , and suggest that primary CD4 + T cells are highly specialised cells, where transcription is subject to tight regulation to avoid excessive energy consumption by the cell and to control effector function. As expected, by normalizing our analysis to a functionally more homogeneous population of memory CD4 + T cells, we observed higher 13 levels of correlation (mean = 0.233), which is consistent with their increased expression of the majority of the assessed T-cell markers. A slightly decreased correlation (mean = 0.178) was observed in in vitro stimulated CD4 + T cells, suggesting an increased variance of protein and mRNA expression in activated CD4 + T cells (Fig. 5g) .
Parallel mRNA and protein profiling provides increased cell-type resolution of the heterogeneous CD45 + immune cell population in blood and tissue
To investigate how this combined targeted scRNA-seq and transcriptomics approach performs on a more heterogeneous population of immune cells, we isolated total CD45 + cells isolated from blood and a matching duodenal biopsy from two coeliac disease (CD) patients with active disease. In this experiment we captured 31,907 single-cells that passed QC and expanded the AbSeq panel to the detection of 68 protein targets ( Table S1 ). As expected, we observed a very defined clustering of the different cell populations representing the CD45 + immune cells ( Fig. 6a) .
Consistent with previous data [26, 27] , we found a clear separation in cells isolated from either blood or the small intestine ( Fig. 6b) , indicating a strong transcriptional signature of tissueresidency. Furthermore, clustering of the cells isolated from either blood ( Fig. 6c and Fig. S5a ) or tissue ( Fig. 6d) separately, revealed clear identification of the expected cell populations. The main distinction was the relative distribution of the main immune populations, with a marked increased representation of B-cell, NK-cell and CD14 + CD16monocyte populations in blood, and a significant increase in the frequency of plasma cells in the small intestine. In agreement with our findings in CD4 + T cells, we found that the acquisition of a memory phenotype was the main driver of the clustering of both CD4 + and CD8 + T cells (Fig. S5b,c) . In addition, we identified other clusters of non-conventional T cells, including a subset of gd T cells and mucosal-associated invariant T cells (MAIT) in blood, which shared similarities with the transcriptional signature of memory CD8 + T cells, marked by the expression of effector-type cytokines genes, such as NKG7 ( Fig. S5c) . In contrast, tissue-resident CD4 + T cells isolated from the small intestine were restricted to a memory phenotype and displayed a markedly different subset distribution, including a substantially enlarged population of FOXP3 + Tregs (Fig. 6e,f) . Moreover, the simultaneous assessment of the protein expression of CXCR5, ICOS and PD-1, identified a cluster of Tfh cells 14 ( Fig. 6e) , which could be distinctly clustered along a trajectory of Tfh-cell activation, as illustrated by the gradient of expression of key Tfh functional transcripts, such as IL21, CXCL13 and BTLA ( Fig. 6g) .
Similarly, we also identified distinct trajectories of cell differentiation in other immune cell types, as illustrated by the gradient of differentiation and class-switching of B cells in blood ( Fig.   S6a-c) . Peripheral B cells were clearly dominated by a naïve IgD + IgM + CD27subset, and only a small fraction of class-switched IgG + CD27 + memory B cells, which was consistent with the young age of the CD patients. In contrast, tissue-resident B cells were much less abundant and contained mostly cells with a class switched IgG + CD27 + memory phenotype. In addition, we identified a vastly expanded population of antibody-secreting plasma cells ( Fig. S6d,e ). Of note, because we were able to specifically assess the expression of the secreted Ig isotypes, we could also discriminate precisely the different functional plasma cell subsets, including a very abundant population of IgA-secreting plasma cells (Fig. S6f) , which are known play a critical role in interaction with the microbiome in the gut. Together, these data provide an example of the power of this multimodal approach to identify trajectories of cell differentiation and cell states in diverse immune cell and tissue types.
Discussion
The advent of scRNA-seq has proved to be a transformative technology that is shaping our understanding of the complexity and function of the human immune system [28, 29] . However, currently, both the elevated costs to perform these experiments, as well as the reliance on transcriptional data alone, pose significant challenges to the widespread practical applicability of these technologies. In this study, we present an integrated, cost-effective, approach to sensitively assess simultaneous expression of mRNA and protein for hundreds of key immune targets at the single-cell level using the AbSeq technology [11] .
Recently, two similar approaches, CITE-seq [9] and REAP-seq [10] , have been described to measure protein expression using oligo-conjugated antibodies in parallel with scRNA-seq data.
Furthermore, other applications are currently being developed to integrate the growing portfolio of single-cell omics technologies [30, 31] . A fundamental difference with the approach described in this study is that these technologies all rely on whole-transcriptome data, providing a high-level cross-sectional representation of all polyA mRNA transcripts in the cell. In contrast, by using targeted scRNA-seq, we are relying on prior knowledge to specifically assess the expression of hundreds of selected genes in single cells. Moreover, a targeted approach provides a more sensitive quantification of expression of the selected genes at a fraction of the cost to generate the sequencing libraries, as it avoids the detection of highly expressed invariant housekeeping genes, which take up the vast majority of the whole-transcriptome scRNA-seq libraries. The increased sensitivity of a targeted approach is particularly relevant for the accurate assessment of lowlyexpressed genes with critical regulatory function, such as transcription factors, which can be poorly quantified using traditional whole-transcriptome scRNA-seq data. It therefore, provides a knowledge-based approach to validate and extend whole-transcriptome scRNA-seq findings, that can be widely implemented in any research or clinical setting. Similarly to other widelyimplemented knowledge-based single-cell immunophenotyping tools such as flow-cytometry and CyTOF, the highly customisable nature of this approach is critical to investigate specific research questions with very high sensitivity and in larger number of samples. However, in contrast to CyTOF which is inherently time-consuming and requires the availability of large numbers of cells to maximise the information generated by each run, this technology is ideally suited for unique and highly valuable clinical samples, for which cell availability and number are major practical 16 constraints. Furthermore, the digital nature and lack of spectral overlap issues with the AbSeq measurements provide a superior specificity and sensitivity compared to flow cytometry for the quantification of lowly-expressed proteins, allowing accurate detection of zero or very low copy numbers, which are usually difficult to discriminate by flow cytometry. A good example was the sensitive quantification of the co-stimulatory protein CD80 by AbSeq, whose expression was found to be restricted to activated T cells. In comparison, flow cytometric assessment of CD80 expression was much less well-resolved with higher background, resulting in lower dynamic range of expression comparing to AbSeq.
The increased sensitivity and high number of parameters simultaneously assessed using this multi-omics approach can also lead to unanticipated novel biological findings. An illustrative example of this potential is the identification of the APC-restricted CD80 and CD86 co-stimulatory proteins as markers of activated Tregs in peripheral blood. Although mechanisms of CD80/86 protein expression on the surface of T cells, including trogocytosis and trans-endocytosis, have been previously demonstrated, they have been restricted to either mouse models or to in vitro cell line models [32] [33] [34] . Our data demonstrate that expression of CD80 and CD86 at the protein level can also be detected in humans on the surface of primary T cells isolated ex vivo from blood, and reveal specific differences between the expression of these two proteins that could provide novel insight into the functional mechanism(s) leading to their expression. Notably, while CD86 expression was remarkably restricted to CTLA-4 hi Tregs and intracellular, CD80 was less dependent on CTLA-4 expression and mostly detected on the surface of T cells. Consistent with these results, the AbSeq data revealed that CD86 expression was restricted to a small subset of memory Tregs displaying hallmarks of a highly activated phenotype, supporting the hypothesis that CD86 molecules captured by CTLA-4 could be transiently expressed on the surface of activated Tregs prior to internalisation and degradation. In contrast to CD86, CD80 protein expression could also be detected in Tregs with lower CTLA-4 levels, and displayed broader expression profile in other activated T-cell subsets. In particular the pseudotime analysis in our dataset, identified CD80 as a marker of the temporal differentiation of Th17 cells, which may provide a mechanistic rationale for the recently reported suppression of Th17 differentiation in response to anti-CD80 treatment in mice [35] . Furthermore, we also note a distinct co-expression of CD80 protein and HLA-class II mRNA (HLA-DRA) in a subset of activated Th1 cells, which could indicate recent activation in the context of strong TCR signaling required to induce the differentiation of Th1 cells [36, 37] .
Owing to the strong upregulation of CTLA-4 on activated T cells, our data cannot provide conclusive evidence for the occurrence of trans-endocytosis in primary human T cells.
Nevertheless, the co-expression between CD86 and CTLA-4 and its restricted expression on activated Tregs, suggest that likely both trogocytosis and trans-endocytosis contribute to the expression of APC molecules on the surface of human primary CD4 + T cells. In addition, we also cannot rule out that the possibility that CD80 and CD86 are specifically expressed on activated CD4 + T cells, but that the mRNA has a very short half-life, a hypothesis that has been previously reported [38] . Nevertheless, these data point to subtle, previously uncharacterized, differences in the expression of CD80 and CD86 in different T cell subsets. To our knowledge, these findings provide the first evidence for the occurrence of these mechanisms in human primary T cells, and indicate that surface expression of CD80 and CD86 could be valuable new markers for the isolation of antigen-specific T cells for functional assays.
Another example of the of the potential of this multi-omics approach to reveal novel biological findings was the identification of a Th1 CD4 + T-cell subset with marked cytotoxic profile that we found to be selectively expanded in an SLE patient. Of interest, this subset displayed a phenotype that is consistent with a population of CXCR3 + PD-1 + CD4 + T cells that were recently found to be expanded in blood from SLE patients [39] . Although our current dataset is limited in patient numbers, the transcriptional profile of the heterogeneous CXCR3 + PD-1 + CD4 + T-cells described by Caielli et al display the same distinct Th1 profile, marked by the expression of the transcription factor TBET and numerous cytotoxic effector molecules. Our data suggest that a specific enrichment with the cytotoxic CD4 + T-cell subset described in this study could be responsible for the reported enrichment of CXCR3 + PD-1 + CD4 + T-cells in SLE patients, and provides additional functional characterisation of this heterogeneous subset at the single-cell level, which could be critical to further investigate its role in the pathogenesis of SLE.
An important finding from this study and other related studies [9, 10] , is the generally low levels of correlation between mRNA and protein expression in primary CD4 + T cells at the singlecell level. One possible explanation for this observation is that reduced sensitivity of scRNA-seq to quantify mRNA expression, may be leading to an underestimation of the correlation 18 coefficients. However, we note that there are notable exceptions, such as CD161, which displayed a high correlation between mRNA and protein levels at 0.847 in memory CD4 + T cells, demonstrating that a systematic error in the quantification of mRNA levels by scRNA-seq technologies is not the only factor contributing to the observed low level of correlation. These findings therefore underscore the importance of parallel protein quantification to better identify stable cellular phenotypes associated with cell function. In contrast to mRNA expression, proteins display a much larger dynamic range of expression and longer half-life [40, 41] , resulting in much higher copy numbers, and a more accurate and reliable quantification compared to their mRNA counterparts. This is particularly relevant in differentiated resting primary cells, such as CD4 + T cells, where transcription is tightly regulated to maintain effector function. These low copy numbers result in increased stochastic variation in mRNA quantification and dropout rate, which impair the accuracy single-cell methods that rely only on transcriptional data. Furthermore, mRNA profiling provides only a snapshot into the current functional state of the cell, which can be better assessed with combined protein expression data. An illustration of the power of this combined multimodal approach is the detailed trajectories of differentiation that we identified in resting primary CD4 + T cells, which were recapitulated by precise gradients of mRNA expression. The sensitivity of these measurements combined with the high numbers of cells analysed lend themselves to identify gradual and subtle changes in cell states, which are critical to identify dynamic changes reflecting mechanisms of functional adaptation in a heterogeneous cell population.
In summary we here show that combined targeted scRNA-seq and protein expression analysis provides a high-resolution map of human immune cells in blood and tissue, and reveals novel biological insights into the biology of CD4 + T cells, as illustrated by the identification of CD80/CD86 expression on activated Tregs in circulation and the functional characterisation of a potential pathogenic cytotoxic CD4 + T-cell subset in SLE. Our data provide a proof-of-principle for the implementation of this integrated approach as a widely applicable, and cost-efficient research tool for immunologists that could be particularly valuable in a clinical setting for the characterisation of rare patient samples with limited cell numbers, as well as to assess the functional consequence at the single-cell level of targeting key biological pathways in vivo, in patients treated with immunotherapeutic drugs. Table S1 .
Methods
Subjects
CD80/86 immunophenotyping
Immunophenotyping of the co-stimulatory molecules CD80/CD86 and CTLA-4 was performed in freshly isolated PBMCs. Cells were initially stained with fluorochrome-conjugated antibodies against surface receptors (see Table S1 ) in BD Brilliant stain buffer (BD Biosciences) for 30 min at room temperature. Fixation and permeabilisation was performed using FOXP3 Fix/Perm Buffer Set (eBioscience) according to the manufacturer's instructions, and cells were then immunostained with fluorochrome-conjugated antibodies against intracellular markers (including CTLA-4, CD80 and CD86 where indicated) in BD Brilliant stain buffer for 45 min at room temperature.
Immunostained samples were acquired using a BD Fortessa (BD Biosciences) flow cytometer with FACSDiva software (BD Biosciences) and analysed using FlowJo (Tree Star, Inc.). 21 For the characterisation of CD45 + immune cells from tissue and tissue, blood-derived PBMCs and paired duodenal biopsies were cryopreserved in CryoStor CS10 reagent (StemCell) and stored in liquid nitrogen until sample processing. Blood-derived PBMCs were processed as described above. The paired duodenal biopsies were thawed at 37ºC in X-Vivo with 1% heat-inactivated, filtered human AB serum then subjected to gentle mechanical dissociation using gentleMACS (Miltenyi Biotec) followed by short 20 min enzymatic dissociation at 37ºC using a very low concentration of Liberase TL (0.042 mg/ml; Sigma), 10 nM HEPES and 1mg/ml DNase I in X-Vivo with 10% FBS. Following enzymatic dissociation, the biopsies were homogenised using a more vigorous gentleMACS cycle and strained through a 70um filter with physical maceration to generate single-cell suspensions. CD45 + immune cells were further enriched using a 70/35% Percoll gradient (Sigma). The dissociation protocol and low concentration of Liberase TL enzyme were optimised to show minimal effect on the degradation of surface protein expression levels, as assessed by flow cytometry. This was critical to ensure maximal sensitivity and specificity of the AbSeq protein quantification in these samples.
Tissue dissociation and isolation of CD45 + immune cells
Blood-and tissue-derived single-cell suspensions were incubated with Fixable Viability Dye eFluor 780 for 15 min at room temperature and total CD45 + cells were isolated by FACS sorting.
Following FACS sorting the individual blood and tissue-derived subsets were incubated with Fc block reagent (BD Biosciences) and Sample Tag antibodies for 20 min at room temperature.
Following three rounds of washing, cells were counted and equal numbers (35,000 cells) of bloodand tissue-derived cells from the same donor were pooled together and incubated with AbSeq antibody mastermix (Table S1) according to the manufacturer's instructions. Cells were then washed two times in cold sample buffer, counted and resuspended in 620 ul of cold sample Buffer at a final concentration of 40 cells/ul for loading on a BD Rhapsody cartridge.
cDNA library preparation and sequencing
Single-cell capture and cDNA library preparation was performed using the BD Rhapsody Express Single-cell analysis system (BD Biosciences), according to the manufacturer's instructions.
Briefly, cDNA was amplified -10 cycles for resting cells and 9 cycles for in vitro activated cells - 22 using the Human Immune Response primer panel (BD Biosciences), containing 399 primer pairs, targeting 397 different genes. The resulting PCR1 products were purified using AMPure XP magnetic beads (Beckman Coulter) and the respective mRNA and AbSeq/Sample tag products were separated based on size-selection, using different bead ratios (0.7X and 1.2X, respectively).
The purified mRNA and Sample tag PCR1 products were further amplified (10 cycles), and the resulting PCR2 products purified by size selection (1X and 1.2X for the mRNA and Sample tag libraries, respectively). The concentration, size and integrity of the resulting PCR products was assessed using both Qubit (High Sensitivity dsDNA kit; Thermo Fisher) and the Agilent 4200 
Data analysis and QC
The FASTQ files obtained from sequencing were analysed following the BD Biosciences Rhapsody pipeline (BD Biosciences). Initially, read pairs with low quality are removed based on read length, mean base quality score and highest single nucleotide frequency. The remaining highquality R1 reads are analysed to identify cell label and unique molecular identifier (UMI) sequences. The remaining high-quality R2 reads are aligned to the reference panel sequences (mRNA and AbSeq) using Bowtie2. Reads with the same cell label, same UMI sequence and same gene are collapsed into a single molecule. The obtained counts are adjusted by BD Biosciences developed error correction algorithms -recursive substitution error correction (RSEC) and distribution-based error correction (DBEC) -to correct sequencing and PCR errors. Cell counts are then estimated, using second derivative analysis to filter out noise cell labels, based on the assumption that putative cells have much more reads than noise cell labels. Thus when cells are 23 sorted in the descending order by number of reads, the inflection point can be observed on a log transformed cumulative curve of number of reads. For the CD45 + sorted cells, due to the heterogeneity of the sample, we observed two inflection points (and two corresponding second derivative minima), and therefore, only cell labels after the second inflection point were considered noise labels. Barcoded oligo-conjugated antibodies (single-cell multiplexing kit; BD Biosciences) were used to infer origin of sample (ie. sorted cell population) and multiplet rate by the BD Rhapsody analysis pipeline.
The DBEC-adjusted molecule counts obtained from the Rhapsody pipeline were imported and the expression matrices were further analysed using R package Seurat 3.0 [42] . Most cells identified as undetermined by the Rhapsody pipeline had low number of features (mRNA and protein reads).
These cells along with other cells with similarly low (<35) number of features were filtered out.
Identified multiplet cells were also filtered out at this stage. A detailed summary of the number of putative captured cells, estimated multiplet rate and number of cells filtered from the analysis in each of the three experiments performed in this study is provided in table S2. The resulting matrices were log normalised using the default parameters in Seurat and the UMI counts were regressed out when scaling data. Uniform Manifold Approximation and Projection (UMAP) was used for dimensionality reduction. The default number of used dimensions of PCA reduction was increased to 30 based on Seurat elbow plot. For clustering, we increased the default resolution parameter value for clustering to 1.2 to obtain more fine-grained set of clusters. Differential expression analysis was performed using negative binomial generalized linear model implemented in Seurat, and integration of data from multiple experiments was performed using a combination of canonical correlation analysis (CCA) and identification of mutual nearest neighbours (MNN), implemented in Seurat 3.0 [43] .
The Seurat objects were further converted and imported to the SCANPY toolkit [44] for consecutive analyses. We have computed diffusion pseudotime according to Haghverdi L et al. [45] which is implemented within SCANPY and used the Partition-based graph abstraction (PAGA) method [18] for formal trajectory inference and to detect differentiation pathways. For visualisation purposes we discarded low-connectivity edges using the threshold of 0.7.
Additionally we have also performed pseudotime analysis using another independent method:
Single-Cell Trajectories Reconstruction (STREAM) [20] . In this case to generate appropriate input 24 files the Seurat objects were subsampled to include N=2,500 cells. The values other parameters not mentioned here were set to default. Table S1 . FACS and AbSeq anti-human monoclonal antibodies used in this study. Table S2 . Summary of the cell capture efficiency and multiplet rates for the experiments performed in this study 
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